Systems pharmacology – Towards the modeling of network interactions

European Journal of Pharmaceutical Sciences

Volumn 94, Issue , 2016, Pages 4-14

  Danhof, Meindert ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Adaptive systems; Convergence; Disease progression; Hysteresis; Interdependency; Multi stationarity; Non adaptive systems; Non linearity; Oscillation; Resilience; Synergy; Variability

Indexed keywords

ARTICLE; BIOLOGY; CONCENTRATION RESPONSE; DISEASE COURSE; DRUG BINDING; DRUG DEVELOPMENT; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG RESEARCH; DRUG TARGETING; FEEDBACK SYSTEM; HYSTERESIS; MODEL; PHARMACODYNAMICS; PHARMACOKINETICS; PHYSIOLOGY; PRIORITY JOURNAL; STEADY STATE; ANIMAL; BIOLOGICAL MODEL; CLINICAL PHARMACOLOGY; HUMAN; PROCEDURES; SYSTEMS BIOLOGY; TRENDS;

ANIMALS; DRUG DISCOVERY; HUMANS; MODELS, BIOLOGICAL; PHARMACOLOGY, CLINICAL; SYSTEMS BIOLOGY;

EID: 84971619918     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2016.04.027     Document Type: Article

References (77)

1. Admiraal, R., van Kesteren, C., Boelens, J.J., Bredius, R.G., Tibboel, D., Knibbe, C.A., Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling. Arch. Dis. Child. 99 (2014), 267–272.
2. Ballinger, T.J., Sanders, M.E., Abramson, V.G., Current HER2 testing recommendations and clinical relevance as a predictor of response to targeted therapy. Clin. Breast Cancer 15 (2015), 171–180.
3. Bauer, J.A., Fung, H.L., Pharmacodynamic models of nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Pharm. Res. 11 (1994), 816–823.
4. Beard, D.A., Liang, S.D., Qian, H., Energy balance for analysis of complex metabolic networks. Biophys. J. 83 (2002), 79–86.
5. Bliss, C.I., The toxicity of poisons applied jointly. Ann. Appl. Biol. 26 (1939), 585–615.
6. Cox, E.H., Kerbusch, T., Van der Graaf, P.H., Danhof, M., Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. J. Pharmacol. Exp. Ther. 284 (1998), 1095–1103.
7. Cox, E.H., Kuipers, J.A., Danhof, M., Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation. Br. J. Pharmacol. 124 (1998), 1534–1540.
8. Dahlem, M.A., Kurths, J., Ferrari, M.D., Aihara, K., Scheffer, M., May, A., Understanding migraine using dynamic network biomarkers. Cephalalgia 35 (2015), 627–630.
9. Danhof, M., Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models. J. Pharmacokinet. Pharmacodyn. 42 (2015), 447–462.
10. Danhof, M., Levy, G., Kinetics of drug action in disease states. I. Effect of infusion rate on phenobarbital concentrations in serum, brain and cerebrospinal fluid of normal rats at onset of loss of righting reflex. J. Pharmacol. Exp. Ther. 229 (1984), 44–50.
11. Danhof, M., de Jongh, J., De Lange, E.C., Della Pasqua, O., Ploeger, B.A., Voskuyl, R.A., Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu. Rev. Pharmacol. Toxicol. 47 (2007), 357–400.
12. Danhof, M., de Lange, E.C., Della Pasqua, O.E., Ploeger, B.A., Voskuyl, R.A., Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol. Sci. 29 (2008), 186–191.
13. Dayneka, N.L., Garg, V., Jusko, W.J., Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokinet. Biopharm. 21 (1993), 457–478.
14. De Cock, R.F., Allegaert, K., Brussee, J.M., Sherwin, C.M., Mulla, H., de Hoog, M., van den Anker, J.N., Danhof, M., Knibbe, C.A., Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration. Pharm. Res. 31 (2014), 2643–2654.
15. de Winter, W., DeJongh, J., Post, T., Ploeger, B., Urquhart, R., Moules, I., Eckland, D., Danhof, M., A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying type 2 diabetes mellitus. J. Pharmacokinet. Pharmacodyn. 33 (2006), 313–343.
16. Dua, P., Hawkins, E., van der Graaf, P.H., A tutorial on target-mediated drug disposition (TMDD) models. CPT Pharmacometrics Syst. Pharmacol. 4 (2015), 324–337.
17. Fang, J., DuBois, D.C., He, Y., Almon, R.R., Jusko, W.J., Dynamic modeling of methylprednisolone effects on body weight and glucose regulation in rats. J. Pharmacokinet. Pharmacodyn. 38 (2011), 293–316.
18. Ferl, G.Z., Theil, F.P., Wong, H., Physiologically-based pharmacokinetic models of small molecules and therapeutic antibodies: mini-review on fundamental concepts and applications. Biopharm. Drug Dispos., 2015.
19. Francheteau, P., Steimer, J.L., Merdjan, H., Guerret, M., Dubray, C., A mathematical model for dynamics of cardiovascular drug action: application to intravenous dihydropyridines in healthy volunteers. J. Pharmacokinet. Biopharm. 21 (1993), 489–514.
20. Garrido, M., Gubbens-Stibbe, J., Tukker, E., Cox, E., von Frijtag, J., Kunzel, D., A, I.J., Danhof, M., van der Graaf, P.H., Pharmacokinetic-pharmacodynamic analysis of the EEG effect of alfentanil in rats following beta-funaltrexamine-induced mu-opioid receptor “knockdown” in vivo. Pharm. Res. 17 (2000), 653–659.
21. Germain, R.N., Meier-Schellersheim, M., Nita-Lazar, A., Fraser, I.D., Systems biology in immunology: a computational modeling perspective. Annu. Rev. Immunol. 29 (2011), 527–585.
22. Gottlieb, A., Stein, G.Y., Oron, Y., Ruppin, E., Sharan, R., INDI: a computational framework for inferring drug interactions and their associated recommendations. Mol. Syst. Biol., 8, 2012, 592.
23. Himebauch, A.S., Zuppa, A., Methods for pharmacokinetic analysis in young children. Expert Opin. Drug Metab. Toxicol. 10 (2014), 497–509.
24. Holland, J.H., Complex adaptive systems. Daedalus 121 (1992), 17–30.
25. Holland, J.H., Studying complex adaptive systems. J. Syst. Sci. Complex. 19 (2006), 1–8.
26. Imming, P., Sinning, C., Meyer, A., Drugs, their targets and the nature and number of drug targets. Nat. Rev. Drug Discov. 5 (2006), 821–834.
27. Jones, H.M., Chen, Y., Gibson, C., Heimbach, T., Parrott, N., Peters, S.A., Snoeys, J., Upreti, V.V., Zheng, M., Hall, S.D., Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. Clin. Pharmacol. Ther. 97 (2015), 247–262.
28. Jonker, D.M., Visser, S.A., van der Graaf, P.H., Voskuyl, R.A., Danhof, M., Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. Pharmacol. Ther. 106 (2005), 1–18.
29. Jusko, W.J., Pharmacokinetics and receptor-mediated pharmacodynamics of corticosteroids. Toxicology 102 (1995), 189–196.
30. Jusko, W.J., Ko, H.C., Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin. Pharmacol. Ther. 56 (1994), 406–419.
31. Kleinbloesem, C.H., van Brummelen, P., Breimer, D.D., Nifedipine. Relationship between pharmacokinetics and pharmacodynamics. Clin. Pharmacokinet. 12 (1987), 12–29.
32. Knibbe, C.A., Krekels, E.H., Danhof, M., Advances in paediatric pharmacokinetics. Expert Opin. Drug Metab. Toxicol. 7 (2011), 1–8.
33. Kohl, P., Crampin, E.J., Quinn, T.A., Noble, D., Systems biology: an approach. Clin. Pharmacol. Ther. 88 (2010), 25–33.
34. Koizumi, Y., Iwami, S., Mathematical modeling of multi-drugs therapy: a challenge for determining the optimal combinations of antiviral drugs. Theor. Biol. Med. Model., 11, 2014, 41.
35. Le Cam, S., Louis-Dorr, V., Maillard, L., Hidden Markov chain modeling for epileptic networks identification. Conf Proc IEEE Eng Med Biol Soc 2013, 2013, 4354–4357.
36. Lemaire, V., Tobin, F.L., Greller, L.D., Cho, C.R., Suva, L.J., Modeling the interactions between osteoblast and osteoclast activities in bone remodeling. J. Theor. Biol. 229 (2004), 293–309.
37. Levy, G., Kinetics of pharmacologic effects. Clin. Pharmacol. Ther. 7 (1966), 362–372.
38. Lon, H.K., Liu, D., Jusko, W.J., Pharmacokinetic/pharmacodynamic modeling in inflammation. Crit. Rev. Biomed. Eng. 40 (2012), 295–312.
39. Maas, H.J., Danhof, M., Della Pasqua, O.E., Prediction of headache response in migraine treatment. Cephalalgia 26 (2006), 416–422.
40. Mandema, J.W., Tukker, E., Danhof, M., In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil. J. Pharmacol. Exp. Ther. 260 (1992), 36–44.
41. Margineanu, D.G., Systems biology, complexity, and the impact on antiepileptic drug discovery. Epilepsy Behav. 38 (2014), 131–142.
42. Movin-Osswald, G., Hammarlund-Udenaes, M., Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra- and interindividual aspects. J. Pharmacol. Exp. Ther. 274 (1995), 921–927.
43. Nagashima, R., O'Reilly, R.A., Levy, G., Kinetics of pharmacologic effects in man: the anticoagulant action of warfarin. Clin. Pharmacol. Ther. 10 (1969), 22–35.
44. Paoletti, C., Hayes, D.F., Molecular testing in breast cancer. Annu. Rev. Med. 65 (2014), 95–110.
45. Ploeger, B.A., van der Graaf, P.H., Danhof, M., Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling. Drug Metab. Pharmacokinet. 24 (2009), 3–15.
46. Post, T.M., Freijer, J.I., DeJongh, J., Danhof, M., Disease system analysis: basic disease progression models in degenerative disease. Pharm. Res. 22 (2005), 1038–1049.
47. Post, T.M., Schmidt, S., Peletier, L.A., de Greef, R., Kerbusch, T., Danhof, M., Application of a mechanism-based disease systems model for osteoporosis to clinical data. J. Pharmacokinet. Pharmacodyn. 40 (2013), 143–156.
48. Ramakrishnan, R., DuBois, D.C., Almon, R.R., Pyszczynski, N.A., Jusko, W.J., Fifth-generation model for corticosteroid pharmacodynamics: application to steady-state receptor down-regulation and enzyme induction patterns during seven-day continuous infusion of methylprednisolone in rats. J. Pharmacokinet. Pharmacodyn. 29 (2002), 1–24.
49. Rowland, M., Peck, C., Tucker, G., Physiologically-based pharmacokinetics in drug development and regulatory science. Annu. Rev. Pharmacol. Toxicol. 51 (2011), 45–73.
50. Sager, J.E., Yu, J., Ragueneau-Majlessi, I., Isoherranen, N., Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: a systematic review of published models, applications, and model verification. Drug Metab. Dispos. 43 (2015), 1823–1837.
51. Schafer, S., Kolkhof, P., Failure is an option: learning from unsuccessful proof-of-concept trials. Drug Discov. Today 13 (2008), 913–916.
52. Schmidt, S., Post, T.M., Peletier, L.A., Boroujerdi, M.A., Danhof, M., Coping with time scales in disease systems analysis: application to bone remodeling. J. Pharmacokinet. Pharmacodyn. 38 (2011), 873–900.
53. Sharma, A., Ebling, W.F., Jusko, W.J., Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. J. Pharm. Sci. 87 (1998), 1577–1584.
54. Sheiner, L.B., Stanski, D.R., Vozeh, S., Miller, R.D., Ham, J., Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin. Pharmacol. Ther. 25 (1979), 358–371.
55. Sime, F.B., Roberts, M.S., Roberts, J.A., Optimization of dosing regimens and dosing in special populations. Clin. Microbiol. Infect. 21 (2015), 886–893.
56. Singh, M.K., Gotlib, I.H., The neuroscience of depression: implications for assessment and intervention. Behav. Res. Ther. 62 (2014), 60–73.
57. Snelder, N., Ploeger, B.A., Luttringer, O., Rigel, D.F., Webb, R.L., Feldman, D., Fu, F., Beil, M., Jin, L., Stanski, D.R., Danhof, M., PKPD modelling of the interrelationship between mean arterial BP, cardiac output and total peripheral resistance in conscious rats. Br. J. Pharmacol. 169 (2013), 1510–1524.
58. Snelder, N., Ploeger, B.A., Luttringer, O., Rigel, D.F., Fu, F., Beil, M., Stanski, D.R., Danhof, M., Drug effects on the CVS in conscious rats: separating cardiac output into heart rate and stroke volume using PKPD modelling. Br. J. Pharmacol. 171 (2014), 5076–5092.
59. Stevens, J., Ploeger, B.A., Hammarlund-Udenaes, M., Osswald, G., van der Graaf, P.H., Danhof, M., de Lange, E.C., Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans. J. Pharmacokinet. Pharmacodyn. 39 (2012), 463–477.
60. Strougo, A., Yassen, A., Krauwinkel, W., Danhof, M., Freijer, J., A semiphysiological population model for prediction of the pharmacokinetics of drugs under liver and renal disease conditions. Drug Metab. Dispos. 39 (2011), 1278–1287.
61. Strougo, A., Eissing, T., Yassen, A., Willmann, S., Danhof, M., Freijer, J., First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development. J. Pharmacokinet. Pharmacodyn. 39 (2012), 195–203.
62. Subramanian, N., Torabi-Parizi, P., Gottschalk, R.A., Germain, R.N., Dutta, B., Network representations of immune system complexity. Wiley Interdiscip. Rev. Syst. Biol. Med. 7 (2015), 13–38.
63. Van der Graaf, P.H., Danhof, M., Analysis of drug-receptor interactions in vivo: a new approach in pharmacokinetic-pharmacodynamic modelling. Int. J. Clin. Pharmacol. Ther. 35 (1997), 442–446.
64. Van der Graaf, P.H., Van Schaick, E.A., Visser, S.A., De Greef, H.J., Ijzerman, A.P., Danhof, M., Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A(1) receptor agonists in rats: prediction of tissue-dependent efficacy in vivo. J. Pharmacol. Exp. Ther. 290 (1999), 702–709.
65. van Schaick, E.A., Kulkarni, C., von Frijtag Drabbe Kunzel, J.K., Mathot, R.A., Cristalli, G., AP, I.J., Danhof, M., Time course of action of three adenosine A1 receptor agonists with differing lipophilicity in rats: comparison of pharmacokinetic, haemodynamic and EEG effects. Naunyn Schmiedeberg's Arch. Pharmacol. 356 (1997), 827–837.
66. Vicini, P., Multiscale modeling in drug discovery and development: future opportunities and present challenges. Clin. Pharmacol. Ther. 88 (2010), 126–129.
67. Visser, S.A., Wolters, F.L., Gubbens-Stibbe, J.M., Tukker, E., Van Der Graaf, P.H., Peletier, L.A., Danhof, M., Mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of GABAA receptor modulators: in vitro-in vivo correlations. J. Pharmacol. Exp. Ther. 304 (2003), 88–101.
68. von Bertalanffy, K.L., General System Theory: Foundations, Development, Applications. 1968, George Braziller, New York 0-8076-0453-4 (revised edition 1976).
69. Voytek, B., Knight, R.T., Dynamic network communication as a unifying neural basis for cognition, development, aging, and disease. Biol. Psychiatry 77 (2015), 1089–1097.
70. Westerhout, J., Ploeger, B., Smeets, J., Danhof, M., de Lange, E.C., Physiologically based pharmacokinetic modeling to investigate regional brain distribution kinetics in rats. AAPS J. 14 (2012), 543–553.
71. Whitacre, J.M., Degeneracy: a link between evolvability, robustness and complexity in biological systems. Theor. Biol. Med. Model., 7, 2010, 6.
72. Yassen, A., Olofsen, E., Romberg, R., Sarton, E., Danhof, M., Dahan, A., Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers. Anesthesiology 104 (2006), 1232–1242.
73. Yassen, A., Olofsen, E., Kan, J., Dahan, A., Danhof, M., Pharmacokinetic-pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats. Pharm. Res. 25 (2008), 183–193.
74. Zhang, Y.X., Artificial neural networks based on principal component analysis input selection for clinical pattern recognition analysis. Talanta 73 (2007), 68–75.
75. Zuideveld, K.P., Maas, H.J., Treijtel, N., Hulshof, J., van der Graaf, P.H., Peletier, L.A., Danhof, M., A set-point model with oscillatory behavior predicts the time course of 8-OH-DPAT-induced hypothermia. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281 (2001), R2059–R2071.
76. Zuideveld, K.P., Van der Graaf, P.H., Newgreen, D., Thurlow, R., Petty, N., Jordan, P., Peletier, L.A., Danhof, M., Mechanism-based pharmacokinetic-pharmacodynamic modeling of 5-HT1A receptor agonists: estimation of in vivo affinity and intrinsic efficacy on body temperature in rats. J. Pharmacol. Exp. Ther. 308 (2004), 1012–1020.
77. Zuideveld, K.P., Van der Graaf, P.H., Peletier, L.A., Danhof, M., Allometric scaling of pharmacodynamic responses: application to 5-Ht1A receptor mediated responses from rat to man. Pharm. Res. 24 (2007), 2031–2039.